` GLENMARK (Glenmark Pharmaceuticals Ltd) vs BSE Sensex 30 Comparison - Alpha Spread

GLENMARK
vs
BSE Sensex 30

Over the past 12 months, GLENMARK has significantly outperformed BSE Sensex 30, delivering a return of 27% compared to the BSE Sensex 30's 6% growth.

Stocks Performance
GLENMARK vs BSE Sensex 30

Loading

Performance Gap
GLENMARK vs BSE Sensex 30

Loading
GLENMARK
BSE Sensex 30
Difference

Performance By Year
GLENMARK vs BSE Sensex 30

Loading
GLENMARK
BSE Sensex 30
Add Stock

Competitors Performance
Glenmark Pharmaceuticals Ltd vs Peers

BSE Sensex 30
GLENMARK
LLY
JNJ
NOVO B
ROG
Add Stock

Glenmark Pharmaceuticals Ltd
Glance View

Market Cap
384B INR
Industry
Pharmaceuticals

Glenmark Pharmaceuticals Ltd., founded in 1977 by Gracias Saldanha, has crafted its journey from a single-product company to a noteworthy player in the global pharmaceutical landscape. Headquartered in Mumbai, India, its growth has been driven by a formidable strategy of focusing on both generics and novel drug discovery. In the fiercely competitive world of pharmaceuticals, Glenmark carved its niche by building a diverse product portfolio that spans across dermatology, respiratory, and oncology segments, among others. The company’s nuanced understanding of therapeutic areas and its pursuit of complex generics have empowered it to not only tap into established markets but also venture into emerging ones across 80 countries. This international strategy, combined with robust research and development infrastructure, underscores how Glenmark leverages scientific innovation to ensure steady revenue streams. At the heart of Glenmark's operations lies its commitment to research-driven growth. The company allocates significant resources to its R&D initiatives, manifesting in state-of-the-art facilities across India, Switzerland, and the U.S. Through these centers, Glenmark focuses on the development of differentiated generic medicines and the discovery of innovative therapeutic molecules. The synergy between its generic and innovative drug segments enables Glenmark to sustain profitability by capitalizing on patent expiries while simultaneously pioneering novel drug therapies. This dual approach not only helps the company secure a competitive position in the pharmaceutical market but also fuels its earnings through a balanced mix of volume-driven sales and premium pricing of differentiated products.

GLENMARK Intrinsic Value
1 000.85 INR
Overvaluation 26%
Intrinsic Value
Price
G
Back to Top